Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 1 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Innate Pharma (PK) | IPHYF | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.20 | 15:00:10 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.20 | 2.20 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 1 | 1 | - | 2.13 - 3.37 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 13:18:48 | 1 | US$ 2.8066 | USD |
Innate Pharma (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 205.39M | 38.14M | - | 61.64M | -7.57M | -0.09 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Innate Pharma (PK) News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IPHYF Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 2.13 | 2.20 | 2.13 | 2.19 | 4,033 | 0.07 | 3.29% |
| 3 Months | 2.52 | 2.65 | 2.13 | 2.23 | 1,533 | -0.32 | -12.70% |
| 6 Months | 2.44 | 2.895 | 2.13 | 2.32 | 1,083 | -0.24 | -9.84% |
| 1 Year | 3.10 | 3.37 | 2.13 | 2.45 | 756 | -0.90 | -29.03% |
| 3 Years | 3.66 | 11.00 | 1.93 | 4.68 | 1,669 | -1.46 | -39.89% |
| 5 Years | 6.60 | 11.00 | 1.93 | 5.13 | 1,602 | -4.40 | -66.67% |
Innate Pharma (PK) Description
| Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells. The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first-in-class antibodies in clinical development in immuno-oncology and a pipeline of preclinical candidates to novel targets and mechanisms. Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Based in Marseille, France, Innate Pharma had 122 employees as at March 31, 2016. The company is listed on Euronext Paris. |
